Board of Directors

Joaquin Duato is Chairman and Chief Executive Officer of Johnson & Johnson, the world’s largest, most diversified healthcare products company. Under his leadership, J&J is now exclusively focused on tackling the toughest health challenges by developing innovative medicines and medtech solutions.

The company’s 130,000 employees work to transform health by building a world where complex diseases are prevented, treated, and cured—and where solutions are smarter, less invasive, and more personalized. Under Joaquin’s leadership, Johnson & Johnson is accelerating healthcare innovation using data science and the latest technology to create breakthroughs in care, from cell therapy to robotic-assisted surgery.

Before becoming CEO in January 2022 and Chairman in January 2023, Joaquin served as Vice Chairman of the Executive Committee, where he led the company’s pharmaceutical and consumer health businesses, as well as technology and global supply chain teams. Over three decades with the company, working across multiple geographies, functions, and business segments, Joaquin developed a deep understanding of the unique role J&J serves in solving patients’ health challenges.

A dual citizen of the U.S. and Spain, Joaquin earned an MBA from ESADE in Barcelona, Spain, and a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona.

Joseph J. Wolk (Joe) is the Executive Vice President and Chief Financial Officer for Johnson & Johnson where he leads the company’s Finance and Global Services organizations and serves on the Company’s Executive Committee.

Joe plays a strategic role in the overall management of the organization and leads the development and execution of the Company’s long-term financial strategy. Additionally, as the financial steward of Johnson & Johnson, Joe’s scope of responsibilities includes driving competitive and profitable growth, generating sustainable cash flow, allocating capital to maximize value creation and managing risk across the entire enterprise.

Prior to assuming his role as CFO in 2018, Joe was the Vice President of Investor Relations for Johnson & Johnson. In his 25-year tenure at the Company, Joe has held a variety of senior leadership roles in several sectors and functions. He served as Vice President of Finance for the Innovative Medicine Group, Vice President of Finance for the MedTech Global Supply Chain and Chief Financial Officer of the North America Innovative Medicine Group.

Joe holds a Bachelor of Science degree in Finance from St. Joseph’s University and earned his Juris Doctor degree from Temple University School of Law. He is also a Certified Public Accountant (CPA).

Jennifer Taubert is Executive Vice President and Worldwide Chairman, Innovative Medicine at Johnson & Johnson, the world’s largest, most diversified, healthcare products company. She is a member of the Corporation’s Executive Committee and leads the Innovative Medicine Group Operating Committee.

Jennifer is a leader in shaping the global strategy of transformational medical innovation for the Innovative Medicine sector, successfully delivering vital new medicines to prevent, treat and cure complex diseases including cancer; immune-related disorders; serious mental illness; cardiovascular disease; retinal disease; and pulmonary hypertension. Under her leadership, J&J Innovative Medicine has become the second-largest pharmaceutical business globally, with more than $50 billion in worldwide revenue. The company has been named No. 1 in the Pharmaceuticals category on Fortune magazine’s “World’s Most Admired Companies” list for 10 consecutive years. And, in recognition of her impact on behalf of patients, Jennifer has been named to Fortune’s “Most Powerful Women” list for the past eight years. She was also named among the “100 Most Influential People in Healthcare” by Modern Healthcare magazine. Before joining Johnson & Johnson, Jennifer held positions of increasing scope and responsibility at Merck and Allergan.

Jennifer is a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America, which represents the country’s leading innovative biopharmaceutical research companies, and she is Chair of the International Committee. She also serves on the National Academy of Medicine’s Leadership Consortium and on the Advisory Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. In addition, Jennifer is a member of the Board of Directors of McDonald’s Corporation.

Jennifer received a bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.

As Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, Tim Schmid is transforming the future of healthcare. The organization is focused on developing and delivering medical technologies that help save lives, change the course of disease, and restore health.

With a presence in nearly every operating room in the world and more than 75 million procedures each year, Johnson & Johnson MedTech is comprised of twelve $1B platforms across orthopaedics, surgery, interventional solutions and vision. Together, these businesses are developing smarter, less invasive, and more personalized solutions to address the world’s most complex diseases.

Tim has been with Johnson & Johnson for more than 30 years and has served in leadership positions spanning numerous multi-billion-dollar businesses on three continents. Most recently, he was Company Group Chairman, Johnson & Johnson MedTech Asia Pacific, where he led the company’s efforts to bring life changing medical technology to patients and become the company’s fastest growing region. Tim has also served as Chief Strategic Customer Officer and President of Ethicon.

Tim is a global healthcare leader and a proven architect of winning teams, delivering above-market performance, leading business transformations and driving innovation across the medical technology industry. He is a champion of diversity and a strong advocate for supporting the communities and partners we serve. He was instrumental in establishing Johnson & Johnson’s global partnership with Operation Smile, focused on bringing safe and effective surgical care to children suffering from cleft lip or cleft palate.

As Executive Vice President, Innovative Medicine, R&D and Johnson & Johnson (J&J) Executive Committee member, John’s mission is to focus the best research and development teams in the world at the intersection of unmet medical need and innovation to change the trajectory of human health. A biomedical research leader with a distinguished career across nonprofit, academia, and industry, John encourages a culture that is fast-paced and open to reimagining how life-saving medicines are discovered, developed and delivered. Employing multiple drug modalities, John’s team works across a wide range of areas, including oncology, immunology, neuroscience, cardiovascular diseases, pulmonary hypertension, and retinal disorders.

Prior to joining Johnson & Johnson in April 2023, John held executive leadership positions at Sanofi and Roche, serving on their respective executive committees. He served as CEO of Sanford-Burnham Medical Research Institute (now Sanford Burnham Prebys) where he established multiple therapeutic area-aligned research centers and platform technology centers. John has authored more than 900 research publications and holds more than 130 patents. He was recognized among the top 10 most cited researchers in life sciences and medicine and still ranks among the world’s top 100 most highly cited scientists. He is a fellow of the American Association for the Advancement of Science and the recipient of many honors and awards.

An accomplished scientist and leader, John holds a Bachelor of Arts in Chemistry from the University of Virginia, Charlottesville and an M.D. and Ph.D. (Immunology) from the University of Pennsylvania School of Medicine.

William N. (Bill) Hait is Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer, and a member of the Johnson & Johnson Executive Committee. Bill oversees the Research and Development Management Committee that focuses on talent development and best-practice sharing within the Company’s R&D community, as well as Company efforts to advance mental health, improve healthcare for the world’s most vulnerable and underserved populations, and meet its obligations around product safety and ethical research, aligned with Our Credo.

Dr. Hait joined J&J in 2007 and served as Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Innovative Medicine Research & Development, from 2011 through 2018. Before that, he was the founding Director of The (Rutgers) Cancer Institute of New Jersey. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey -- Robert Wood Johnson Medical School.

Dr. Hait joined the Yale University School of Medicine faculty in 1984 and became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. He is Board Certified in Internal Medicine and Medical Oncology.

He devoted time to numerous advisory and editorial boards, served in a range of scientific functions, societies and committees, was elected President of the American Association for Cancer Research (2007– 2008) and has received numerous awards and honors.

Jim Swanson is Executive Vice President, Chief Information Officer, and member of the Executive Committee for Johnson & Johnson. He is responsible for accelerating Johnson & Johnson’s business outcomes and advancing human health with technology and digital innovation.

In his current role, Jim leads more than 4,000 Technology professionals across 50 countries who are passionate about combining deep scientific expertise with the latest digital solutions to confront complex healthcare challenges. In addition, Jim and his team are responsible for powering 130,000 Johnson & Johnson colleagues and the digital ecosystem that connects the Company to patients and customers.

Jim and the organizations he has led have received industry accolades for their contributions in leadership, application of technology to drive outcomes and deliver business value, best places to work in IT, and support of STEM for emerging talent.

Jim rejoined Johnson & Johnson in 2019 from Bayer Crop Science, where he served as a member of the Executive Leadership Team, Chief Information Officer, and Head of Digital Transformation. Previously, he served as Chief Information Officer at Monsanto, and prior to that, Vice President and Chief Information Officer for Johnson & Johnson Pharmaceutical’s Research & Development organization. Throughout his career, he has had extensive international experience, including living in the United Kingdom and Germany.

Jim holds a bachelor's degree in Bioscience and Biotechnology and a master's degree in Computer Science, both from Drexel University.

Hani Abouhalka is Company Group Chairman for Robotics and Digital, shaping Johnson & Johnson MedTech’s digital transformation by connecting clinically differentiated surgical instruments, surgical robotics systems, and a software ecosystem supporting AI-enabled software solutions.

In this role, Hani has end-to-end responsibility for the robotics and digital programs, a critical priority for Johnson & Johnson MedTech. The portfolio includes differentiated flexible robotics and general surgery robotics, including the MONARCH™ Platform and OTTAVA™, as well as the MedTech Digital ecosystem. He leads cross-functional commercial and R&D teams to deliver transformative and meaningful innovative technologies that address unmet clinical needs and change standards of care, creating a future where medical intervention is smarter, less invasive, and more personalized.

Hani has a strong track record of driving transformational growth across developed and emerging markets, building high-performing teams and championing Credo values, with positive and ethical leadership. Most recently, while serving as Company Group Chairman, MedTech EMEA, Hani returned the business to solid operational growth, increasing market share for virtually every platform, as the organization made significant strides to advance a diverse, winning culture. He supported the ongoing evolution of organizational business models to best match customer needs and built new capabilities in support of digital transformation, such as omnichannel marketing, intelligent automation, and experimentation.

Since joining Johnson & Johnson in 2000, Hani has held several leadership roles across multiple functions, businesses, and geographies. He holds a bachelor’s degree in Biology from Arizona State University and a master’s degree in International Business from the Thunderbird School of Global Management.

Michael Bodner is the Global Head of Heart Recovery where he is responsible for Abiomed. Prior to Abiomed, Michael led Johnson & Johnson’s Cardiac Electrophysiology business as the WW President, Biosense Webster.

Prior to joining Johnson & Johnson, Michael spent 10 years with Abbott most recently as the Divisional Vice President, Endovascular Global Market Development and US Endovascular Sales. He also served as the General Manager, Endovascular, Asia Pacific and Japan, General Manager, South East Asia, Marketing Director, Asia Pacific and Country Manager, Endovascular Australia and New Zealand.

Michael has an undergraduate degree in Biology and Economics from the University of Virginia, a MBA from the Queensland University of Technology in Brisbane, Australia and a Doctorate in Biotechnology from the University of Queensland in Brisbane, Australia.

Aldo Denti is Company Group Chairman of Johnson & Johnson MedTech’s orthopaedics business. In this role, he leads the DePuy Synthes team, with a global reach of products that help more than 6 1/2 million people each year.

Since becoming Company Group Chairman in 2019, Aldo has grown the business to $9 billion, including four platforms with greater than $1B in sales and the largest trauma and extremities business globally. Aldo has transformed the business from an implant driven business to a digitally driven medtech organization driving growth across all key platforms and geographies. This growth comes in the wake of a global pandemic that created a backlog of orthopedic procedures and global supply chain issues.

No stranger to a turnaround, Aldo previously served as Global Franchise Leader at Johnson & Johnson Vision where he modernized the organization and added critical new skill sets in the areas of strategic planning, insights & analytics, e-commerce and business model innovation, and the successful integration of three acquired assets.

Prior to his years at J&J Vision, Aldo held a variety of leadership positions in EMEA for DePuy Synthes, and sales and marketing roles outside the company.

Aldo speaks six languages and holds a bachelor’s degree with honours from York University in Toronto, Canada. He is a father of three, and member of the Board of Governors, College of Business, at Florida State University, and a board member for the AO Foundation.

Celine Martin is Company Group Chairman, Cardiovascular & Specialty Solutions (CSS) Group. CSS is a collection of Johnson & Johnson high-growth global MedTech businesses. This includes the Acclarent, Biosense Webster, Cerenovus, and Mentor teams. These teams work at the intersection of biology and technology to help more than 1.5 million patients each year in the areas of electrophysiology, neurovascular, ENT (ear, nose & throat), and breast reconstruction and aesthetics.

Throughout her 27-year career at Johnson & Johnson, Celine has played a vital role in advancing the ambition of Johnson & Johnson MedTech, including developing new categories and advancing standards of care for atrial fibrillation, stroke, and minimally invasive surgery. Based in Irvine, California, she also helped establish a West Coast hub for Johnson & Johnson.

An active member of the Orange County community, Celine is proud to serve as a board member of Octane OC and an executive committee member of the CEO Leadership Alliance Orange County, two organizations working to accelerate the local economy and attract world-leading talent.

Celine is also an active supporter of women in business and STEM – ensuring diversity, equity, and inclusion programs are in place to support the therapeutic areas where her businesses operate and building a leadership team that is majority female. She has received accolades for her efforts including Los Angeles Times Inspirational Women Honoree, Fierce Biotech Fiercest Women in Life Sciences, Orange County Business Journal DE&I Index, and more.

Celine is a believer in life-long learning and holds an MBA from Wake Forest University and a master’s degree in marketing management from EM Normandie Business School. She has also completed several executive programs through Harvard Business School, INSEAD, and MIT Sloan School of Management.

Peter Menziuso is Vision Company Group Chairman for Johnson & Johnson MedTech. Throughout his 30+ year career at Johnson & Johnson, Peter has built a reputation as a highly inclusive global leader. He has driven turnarounds and transformations, consistently leading businesses to high growth by articulating a compelling vision and strategy, building high-performing teams, and driving accountability to what matters most. Peter has spent half of his career in roles outside of the U.S. and has deep experience across the healthcare industry –spanning pharmaceutical, biotech, and medical devices in a variety of therapeutic areas.

A substantial part of Peter’s experience has been based in eye health. Prior to his appointment as Company Group Chairman, Peter was Worldwide President for Vision Care. In this role, he accelerated growth, while creating and raising standards of eye care around the world and shaped a portfolio of contact lens solutions to deliver healthy sight for life. He also previously served as U.S. President for Vision Care, where he built a deep connection and appreciation of the eye health industry.

Peter has also served as President, North America, Cardiovascular & Metabolism, Johnson & Johnson Innovative Medicine, where he helped transform the business to a period of dynamic growth. His earlier roles within Johnson & Johnson include Vice President, Worldwide Marketing; Vice President, U.S. Sales and Market Development; and General Manager, Canada for LifeScan.

Peter has been actively engaged in key policy issues, having served as co-chair of the Healthcare Alliance for Patient Safety, which advocates patient-focused vision protection policies, as well as acting as chair of the MEDEC (Canada’s innovative medical technology industry trade association) Diabetes Committee. This year, he joined the board of directors for the Ophthalmology Foundation.

Ahmet Tezel, Ph.D. is Company Group Chairman and Global Head of MedTech Innovation and R&D at Johnson & Johnson. With nearly two decades of experience in research and development, Ahmet leads end-to-end R&D for the Johnson & Johnson MedTech portfolio focusing on smarter, less invasive, and more personalized solutions across the orthopaedics, surgery, and interventional solutions businesses, as well as global Regulatory and Pre-Clinical, Clinical, and Medical Affairs.

Previously, Ahmet served as Worldwide Vice President of R&D for the surgical technologies business of Johnson & Johnson where he increased the R&D pipeline value over two-fold. Ahmet led the R&D strategy and overall activities for the wound closure, biosurgery, endomechanical, and energy platforms and products. He created synergies across global teams to enhance integration of technology platforms and utilization of product development best practices. These synergies led to the introduction of a new, optimized project leadership office and structure for the Company’s general surgery robotic platform – to enable faster decision making, sharper accountability, and stronger people leader development.

With broad experience in the medical technology industry, Ahmet has a strong history of driving innovation strategy and delivering new products to market.

Prior to Johnson & Johnson, Ahmet was the Surgical Franchise Head of R&D at Alcon. Under his leadership, he directed a surgical R&D team of more than 800 employees and oversaw an array of products in the surgical pipeline. He also served as the Vice President of R&D for medical devices at Allergen. During that time, he successfully integrated three independently operating product development groups into a cross-functional, highly efficient single unit.

Ahmet is on the External Advisory Board for the Chemical Engineering Department at University of California, Santa Barbara (his alma mater), where he received his Chemical Engineering Ph.D. in transdermal drug delivery and vaccination. He also holds a B.Sc. and M.Sc. in Chemical Engineering from Bogazici University in Istanbul, Turkey.

Jess was appointed to Vice President, Investor Relations in November, 2021. In this role, Jess is responsible for strategically positioning and enhancing the reputation of Johnson & Johnson with key stakeholders, building and maintaining relationships with the investor community, leading the quarterly earnings report with analysts and managing critical shareholder events.

Most recently, Jess served as the Vice President, Finance, Innovative Medicine EMEA where she provided finance leadership for the EMEA region of the Innovative Medicine organization, overseeing the delivery and analysis of financial performance, risk and opportunity assessments and maintenance of a strong compliant environment.

Prior to joining Johnson & Johnson, Jess has 18 years of industry experience across the US, Belgium and Switzerland. She held several Finance positions of increasing responsibility in Corporate, Sales Operations, developed and emerging markets and has played a critical role in finance and business transformations, as well as large integrations and separations.

Jess holds a bachelor’s degree in Finance and Accounting from Miami (of Ohio) University and an MBA from the Kellogg School of Management at Northwestern University.

Tom Cavanaugh is a results-focused leader who has an outstanding ability to navigate through complex environments, grow talent and inspire teams to achieve new possibilities. Recently appointed as the Company Group Chairman, North America, Tom is a member of the Innovative Medicine Group Operating Committee and responsible for leading our efforts to transform the health of people in the U.S. and Canada who face a range of common and rare, complex diseases across our areas of focus.

Prior to his new appointment, Tom was Company Group Chairman, Global Commercial Strategy Organization, and led the development of our commercial strategy for pipeline and in-market assets in close collaboration with R&D, Business Development, and Commercial leaders around the world. This included a robust evaluation of our portfolio and external innovation opportunities, enabling us to invest deeply where we are poised to have the greatest impact.

Tom has a 27-year career in the industry. He joined J&J in 2017 as President of U.S. Oncology and led the organization to become the industry’s fastest-growing multibillion-dollar oncology business. Later as President of U.S. Immunology, Tom led his team to deliver all-time high business results through the COVID pandemic.

Prior to joining J&J, Tom helped build Celgene into a global biopharmaceutical company through leadership positions in marketing, general management, medical affairs and product development. Early in his career, Tom held roles in sales, product management and as a chemist and pharmacy tech after receiving a Bachelor’s in Chemistry from North Carolina State University.

Peter is the Worldwide Vice President, Neuroscience Global Commercial Strategy Organization for Johnson & Johnson Innovative Medicine. He is responsible for developing and driving commercial strategies for the Neuroscience portfolio and pipeline within neuropsychiatric, neurodegenerative and autoantibody-driven diseases of the nervous system.

Prior to Johnson & Johnson, Peter was Senior Vice President, Head of the U.S. Specialty Care Franchise at Boehringer Ingelheim (BI), responsible for a portfolio of therapies across Interstitial Lung Diseases, Oncology, Dermatology, Biosimilars and Mental Health. Peter joined BI as Senior Vice President, Global Therapeutic Area Head Inflammation.

Previously, Peter held multiple senior leadership positions at Baxter, Baxalta, Shire and Takeda, where he was directly responsible for businesses in the U.S., Europe, Middle East, Africa, Asia Pacific and China. He also has been a leader in Global, Regional and International Marketing roles in Hematology, Immunology and Devices and Digital Therapeutics.

Peter began his career, working in venture capital, strategy and business development roles in technology. He holds a degree in Economics from the Wharton School of the University of Pennsylvania.

Peter F. Lebowitz, M.D., Ph.D. leads a world class team responsible for end-to-end discovery through full clinical development and life cycle advancement for Johnson & Johnson in Oncology R&D. This team has delivered the company’s robust oncology pipeline and portfolio that includes small molecules, advanced biologics, cell therapies, vaccine platforms, translational research, diagnostics, and immuno-oncology. Under Peter’s leadership, J&J has achieved many noteworthy milestones including 14 new medicines approved since 2011, with several first and/or best-in-class therapies; 12 U.S. FDA Breakthrough Therapy Designations; and 38 New England Journal of Medicine publications.

Peter has also successfully established an external innovation strategy to advance science and novel therapeutics in core disease areas, including hematologic malignancies, prostate cancer, immuno-oncology lung cancer and bladder cancer. The combination of these efforts has resulted in innumerable strategic partnerships and continues to distinguish J&J as a global oncology innovator.

Prior to his appointment as Global Oncology Therapeutic Area Head, Peter served as the Hematologic Malignancy Disease Area Leader. In this role, he had responsibility for creating the scientific strategy to drive innovation across multiple diseases. Together with his team, Peter is recognized for building an industry-leading hematologic malignancy portfolio that has been foundational for scientific innovation and transformed patient care.

Before joining Innovative Medicine R&D, Peter held Vice President positions in Discovery and Early/Late-Stage Clinical Development for GlaxoSmithKline where he successfully filed ten Investigational New Drug applications and played a significant role in the global registration of three oncology medicines. During his tenure, he also led major programs from preclinical discovery through pivotal Phase 3 registration trials.

Peter graduated magna cum laude from Harvard University, holds a master’s degree in Health Care Policy from Oxford University, and earned his MD/PhD from the University of Pennsylvania School of Medicine. He completed his postgraduate clinical training in Internal Medicine at Duke University Medical Center and his Hematology/Oncology fellowship at the National Cancer Institute, National Institutes of Health. He has been board certified in Internal Medicine and Medical Oncology.

As a physician and researcher, David’s career reflects his desire to make a difference in patients’ lives through the pursuit of compelling science and business innovation. David joined Johnson & Johnson in September 2018, as the Global Therapeutic Area Head for Innovative Medicine Immunology, where he leads a team focused on discovering and developing treatments for immune-mediated diseases. Under his leadership, Immunology researchers are working to build on the success of our current portfolio, which includes STELARA® and TREMFYA®, two of Johnson & Johnson’s largest products.

Before joining Johnson & Johnson, David was based in Basel, Switzerland, where he served as Global Head, Immunology, Inflammation and Infectious Disease Discovery and Translation Area for Roche, and prior to that, as Global Head of Autoimmunity, Dermatology, and Transplant Translational Medicine at the Novartis Institutes for BioMedical Research. In each of these roles, he led on the strategic approaches that fed those companies’ pipelines, prioritized assets, and accelerated their development. His ability to develop external collaborations and to lead and develop his teams was central to his success in each organization.

Before joining industry, David practiced Rheumatology and ran an NIH-funded translational research laboratory at Brigham and Women’s Hospital/Harvard Medical School. While there, he was an active author and speaker, with more than 80 peer reviewed publications and book chapters, and more than 100 lectures/seminars. As a precursor to his career in industry, while at Harvard, he also founded/co-founded three companies, securing venture capital funding. Ultimately, one – a biotech – was acquired by a major pharmaceutical company.

David earned his MD as well as a PhD in Microbiology/Immunology from the Duke University School of Medicine. His passion for developing new medicines is rooted in his experiences treating patients as a practicing rheumatologist.

Candice Long is the Worldwide Vice President for the Immunology Therapeutic Area with Johnson & Johnson Innovative Medicine. Together with the R&D Global Therapeutic Area Head for Immunology, she has end-to-end responsibility for the Immunology portfolio and pipeline, leading global commercial efforts to build and maximize value in areas of high unmet need.

In her former role as U.S. President, Infectious Diseases & Vaccines (ID&V), Candice was responsible for steering the ID&V business to deliver on near- and long-term growth objectives to advance the Company’s HIV portfolio, strengthening organizational readiness to introduce vaccines, and leading ongoing efforts to expand the breadth of the business.

Prior to that role, Candice was Vice President of Marketing for U.S. Immunology. During that time, the business grew significantly with the successful launch of TREMFYA® (guselkumab) for psoriasis and STELARA® (ustekinumab) for ulcerative colitis, with increased focus on fulfillment through new support services while effectively protecting patients’ ability to maintain success on their STELARA and REMICADE® (infliximab) treatments. Candice began her career at Johnson & Johnson and has held various other roles with increasing responsibilities in the Pharmaceuticals and Consumer sectors.

Passionate about digital innovation and advocacy in healthcare, Candice has also served as the Executive Sponsor the Company’s comprehensive employee giving program. In addition, she served as an Executive Sponsor of the Company’s Employee Resource Group, Open&Out, a global network of LGBTQ+ and Ally individuals who seek to make a difference by creating safe and inclusive workspaces, fostering healthier communities, and empowering employees.

Candice earned an MBA from the College of William & Mary in Williamsburg, Virginia, and a Bachelor of Science in Business Administration and Bachelor of Arts in History from Mary Washington College in Fredericksburg, Virginia.

Bill leads the Neuroscience therapeutic area of Johnson & Johnson Innovative Medicine in discovering and developing important new therapies for people living with brain disorders.

Prior to joining Johnson & Johnson, Bill held the position of President and Chief Executive Officer of Blackthorn Therapeutics, and previously served as the company’s Chief Scientific Officer and Head of R&D. Before Blackthorn, Bill held multiple leadership positions at Theravance Biopharma and Merck.

Bill received a bachelor’s in Psychology from Swarthmore College and a doctorate in Experimental Psychology from Brown University. He conducted postdoctoral research at the Keck Center for Integrative Neuroscience at the University of California, San Francisco. He has published extensively on neuroscience and brain disorders, with more than 75 publications in scientific journals.

Biljana Naumovic is Worldwide Vice President, Oncology, for Johnson & Johnson. Working in collaboration with the R&D organization, Biljana is responsible for the development of breakthrough commercial strategies to deliver a sustainable and differentiated oncology pipeline. In this role, she oversees multiple functions that support the Global Oncology business such as Strategic Marketing, Market Access, Medical Affairs, Portfolio, and Strategic Analytics.

Prior to this appointment, Biljana held the position of Managing Director, Australia & New Zealand where she oversaw a cultural transformation and reorganization of the business, culminating in double digit growth in 2021. Biljana first joined J&J in 2019 as Vice President, Oncology for Europe, the Middle East and Africa (EMEA), where she was responsible for creating and delivering the commercial strategy across the solid tumor portfolio and pipeline spanning prostate cancer, bladder cancer, and lung cancer, as well as multiple novel tumor pathways.

Before joining J&J, Biljana held a number of senior positions at AstraZeneca, including Vice President of Commercial for Europe where she was responsible for strategy across oncology, respiratory and cardio metabolic therapy throughout Europe, including commercial effectiveness and digital platforms. While at AstraZeneca Biljana oversaw the successful launch of three core assets in solid tumors, immuno-oncology and targeted therapy.

Biljana has a passion for people development and throughout her career has mentored diverse talent across multiple organizations, expediting growth and enabling cross-functional, cross-regional and global development opportunities. During her time with J&J, she has supported the establishment of two core disease area teams in lung cancer and bladder cancer, as well as diagnostics.

Biljana is a physician by training and graduated in 2001 from the Belgrade University Medical School. She worked as a practicing physician for several years before transitioning to industry. Biljana also holds an executive education degree from the London Business School.

Erik Haas joined Johnson & Johnson as the Worldwide Vice President for Litigation on November 2, 2020. In this role, Erik is responsible for the Company’s diverse and robust litigation docket, driving litigation strategy, advising internal stakeholders on litigation issues, and engaging with the external environment on litigation policy matters. He manages the Company’s litigation practice groups, which include product liability, patent and other intellectual property, government claims, commercial, competitive law, employment and litigation policy and risk mitigation.

Prior to joining Johnson & Johnson, Erik was a partner at the law firm Patterson Belknap & Tyler LLP. During his three-decade tenure at the firm, Erik was lead outside litigation counsel and legal advisor for Johnson & Johnson and its Board of Directors, as well as for other major firms and international conglomerates. Throughout his career, Erik litigated and tried cases in each of the practice areas that he now manages, and led the firm’s complex commercial, securities and structured finance, False Claims Act, and art litigation groups.

While at Patterson Belknap, Erik also served in various roles for non-profit legal organizations including, notably, as the President of the Board of Directors and Chair of the Audit, Finance and Investment Committee for the Legal Services of the Hudson Valley, one of largest non-profit legal organizations in the State.

Erik joined Patterson Belknap Webb & Tyler in 1993 upon his graduation with honors from New York University Law School. Prior to attending law school, Erik spent three years as an auditor and consultant with Arthur Andersen & Company, where he focused on structured finance and securitization transactions, and obtained his CPA license. Erik graduated magna cum laude with a business degree from the State University of New York.